To the Editor: Nair et al. (June 22 issue)1 found in the ZONDA trial that the median blood eosinophil counts fell dramatically after treatment with benralizumab. In a previous trial, Bleecker et al.2 found that blood eosinophil counts were reduced by benralizumab treatment. To avoid bias, what was done to prevent unmasking of the trial-group assignment to the investigators by means of the patients’ eosinophil counts? To the Editor: Nair and colleagues found that benralizumab showed significant, clinically relevant benefits, as compared with placebo, on oral glucocorticoid use and exacerbation rates. However, certain proportions of patients who smoke were enrolled . . .

中文翻译：

---

哮喘中贝那利珠单抗的糖皮质激素保留

致编辑：Nair等。（6月22日发行）1在ZONDA试验中发现，使用贝那利珠单抗治疗后，嗜酸性粒细胞的中位数显着下降。在先前的试验中，Bleecker等[2]发现通过贝那利珠单抗治疗可减少血液嗜酸性粒细胞计数。为避免偏见，采取了什么措施来防止通过患者的嗜酸性粒细胞计数揭露试验组对研究者的影响？致编辑：Nair及其同事发现，与安慰剂相比，贝那利珠单抗对口服糖皮质激素的使用和恶化率具有显着的临床相关益处。但是，有一定比例的吸烟患者入组。。。